[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020

June 2020 | 500 pages | ID: GDD497A78CBEN
CurrentPartnering

US$ 3,495.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
SUMMARY

The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare companies.

DESCRIPTION

The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:

Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading monoclonal antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2014. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.

Key benefits

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 provides the reader with the following key benefits:

In-depth understanding of monoclonal antibodies deal trends since 2014
Access to headline, upfront, milestone and royalty data
Access to the structure of monoclonal antibodies agreements with numerous real life case studies
Comprehensive access to over 800 actual monoclonal antibodies deals entered into by the world’s biopharma companies
Identify the leading monoclonal antibody partnering companies
Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2020 is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2020 includes:

Trends in monoclonal antibodies dealmaking in the biopharma industry since 2014
Analysis of monoclonal antibodies deal structure
Access to headline, upfront, milestone and royalty data
Access to over 800 monoclonal antibodies deal records
The leading monoclonal antibodies deals by value since 2014
Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2014

In Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Monoclonal antibodies type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 report provides comprehensive access to available deals and contract documents for over 800 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise monoclonal antibody rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?


BENEFITS

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 provides the reader with the following key benefits:

In-depth understanding of monoclonal antibodies deal trends since 2014
Access to headline, upfront, milestone and royalty data
Acces to the structure of monoclonal antibodies agreements with numerous real life case studies
Comprehensive access to over 800 actual monoclonal antibodies deals entered into by the world’s biopharma companies, together with real world clause examples
Full listing of monoclonal antibodies deals by company A-Z, deal value, phase of development, deal type, and therapy focus
Identify leading monoclonal antibodies deals by value since 2014
Identify the most active monoclonal antibodies dealmakers since 2014
Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
EXECUTIVE SUMMARY

CHAPTER 1 – INTRODUCTION

CHAPTER 2 – TRENDS IN MONOCLONAL ANTIBODY DEALMAKING

2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody partnering by deal type
2.5. Monoclonal antibody partnering by therapy area
2.6. Deal terms for monoclonal antibody partnering
  2.6.1 Monoclonal antibody partnering headline values
  2.6.2 Monoclonal antibody deal upfront payments
  2.6.3 Monoclonal antibody deal milestone payments
  2.6.4 Monoclonal antibody royalty rates

CHAPTER 3 – LEADING MONOCLONAL ANTIBODY DEALS

3.1. Introduction
3.2. Top monoclonal antibody deals by value

CHAPTER 4 – MOST ACTIVE MONOCLONAL ANTIBODY DEALMAKERS

4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody partnering company profiles

CHAPTER 5 – MONOCLONAL ANTIBODY CONTRACTS DEALMAKING DIRECTORY

5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory

CHAPTER 6 – MONOCLONAL ANTIBODY DEALMAKING BY TECHNOLOGY TYPE

Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb

CHAPTER 7 – PARTNERING RESOURCE CENTER

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

APPENDICES

Appendix 1 – Monoclonal antibody deals by company A-Z
Appendix 2 – Monoclonal antibody deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 – Monoclonal antibody deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 – Monoclonal antibody deals by therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Hematology
Hospital care
Immunology
Infectives
Metabolic
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory
Appendix 5 –Deal type definitions

ABOUT WILDWOOD VENTURES

Current Partnering
Current Agreements
Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Therapeutic antibody definitions
Figure 2: Monoclonal antibody partnering since 2014
Figure 3: Active monoclonal antibody dealmaking activity since 2014
Figure 4: Monoclonal antibody partnering by deal type since 2014
Figure 5: Monoclonal antibody partnering by disease type since 2014
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2014
Figure 11: Most active monoclonal antibody dealmakers since 2014
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events

COMPANIES MENTIONED

3D Medicines, 3rd People’s Hospital of Shenzhen, 3SBio, 4D Pharma, Abbvie, Abcam, AbCellera, AbCheck, AbClon, ABL Bio, Ablexis, Ablynx, Abpro, Abveris, Abzena, Acceleron Pharma, Accord Healthcare, Acerta Pharma, Achaogen, Acticor Biotech, Actinium Pharmaceuticals, Adaptimmune, Adaptive Biotechnologies, Adimab, Adlai Nortye, Aduro BioTech, Advanced BioScience Laboratories, Advaxis, Aeglea BioTherapeutics, Aevi Genomic Medicine, AffaMed Therapeutics, Affimed Therapeutics, Affinita Biotech, AGC Biologics, Agenus Bio, Agilvax, Aimmune Therapeutics, Ajinomoto, Ajinomoto Bio-Pharma Services, Alder Biopharmaceuticals, Alector, Alexion Pharmaceuticals, Allergan, Alligator Bioscience, Almac Group, Almirall, Alphamab Biopharmaceuticals, Alvogen, Alvotech, Alzheimer's Drug Discovery Foundation, Ambrx, Amgen, Amneal Pharmaceuticals, Amplyx Pharmaceuticals, AnaptysBio, AnGes MG, Antengene, Anthera Pharmaceuticals, Antidote Therapeutics, Antigen Express, Antitope, Apceth, Apeiron Biologics, Aperion Biologics, Apexigen, APRINOIA Therapeutics, Arcus Biosciences, arGEN-X, argenx, Aridis Pharmaceuticals, ARMO Biosciences, Array Biopharma, Arsanis Biosciences, Ascenion, Ascentage Pharma, Aslan Pharma, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Atara Biotherapeutics, Athenex, Atlab Pharma, AvantGen, Avantor, AVEO Oncology, Avid Bioservices, Avidity Biosciences, Aytu BioScience, Back-A-Line, Basilea Pharmaceutica, Bausch & Lomb, Bavarian Nordic, Baxalta, Bayer, Bayer Healthcare, Baylor Institute for Immunology Research, BB100, BeiGene, BerGenBio, Berkeley Lights, Biametrics, Bill and Melinda Gates Foundation, Bio-Thera Solutions, BioArctic Neuroscience, BioAtla, Biocare Medical, Bioceros, BiocerOX Products, Biocon, Biodesix, BioDuro, Bioeq IP, Biofactura, Bio Farma, Biogen, BioInvent, BiolineRX, BioMarker Strategies, Biomedical Advanced Research and Development Authority, Biomunex Pharmaceuticals, Bioncotech Therapeutics, BioNTech, BioRap Technologies, Biothera, BioVectra, BioXcel, BliNK Biomedical, BliNK Therapeutics, Bluebird Bio, Boehringer Ingelheim, Bpifrance, Brigham and Women's Hospital, Brii Biosciences, Bristol-Myers Squibb, C-Bridge Capital, C2N Diagnostics, Caelum Biosciences, Caliber Biotherapeutics, California Institute for Regenerative Medicine, Calithera Biosciences, Calypso Biotech, Cancer Prevention and Research Institute of Texas, Cancer Research Technology, Cancer Research UK, CanCure, Candel Therapeutics, Cantargia, Catalent, CBT Pharmaceuticals, CDI Laboratories, Celexion, Celgene, Celimmune, Celldex Therapeutics, Cellectis, Cell Marque, Cellmid, Cell Signaling Technology, Celltrion, Celsius Therapeutics, Center for iPS Cells Research and Application, Centre for Drug Research and Development (CDRD), Checkmate Pharmaceuticals, Chi-Med, Chiome Bioscience, Chugai Pharmaceutical, Cilag AG, Cipla, City of Hope, City of Hope Comprehensive Cancer Center, Clal Biotech, Clinica Universidad Navarra, Clovis Oncology, CMAB Biopharma, CMC Biologics, Coherus Biosciences, Cold Genesys, Columbia University, Complement Pharma, Compugen, Conkwest, ContraFect, Cook Pharmica, Corvidia Therapeutics, Corvus Pharmaceuticals, Covalab, Crescendo Biologics, Cromos Pharma, Crown Bioscience, CR Pharma, Crystal Bioscience, CSL, CSPC Pharmaceutical Group, CStone Pharmaceuticals, Cue Biopharma, Cullinan Oncology, Curant Health, CureTech, Curie-Cancer, Cytodyn, CytomX Therapeutics, Cytovance Biologics, Daiichi Sankyo, Dako, Debiopharm, DecImmune Therapeutics, Defense Advanced Research Projects Agency, Defyrus, Denali Therapeutics, DendroCyte, Department of Defense, Department of Health and Human Services, Dermira, Diaprost, Disc Medicine, Distributed Bio, DNAtrix, Dyadic International, Dynavax Technologies, EA Pharma, Eddingpharm, eFFECTOR Therapeutics, EirGenix, Eisai, Eleven Biotherapeutics, Eli Lilly, ElsaLys Biotech, EluSys Therapeutics, EMD Millipore, EMD Serono, Emergent BioSolutions, Enthera, Enumeral Biomedical, Enzo Biochem, Epirus Biopharmaceuticals, EpiThany, Equillium, Essex Bio-Technology, Eureka Therapeutic, Eurofarma, European Union Regional Development Fund, EUSA Pharma, Eutilex, Everest Medicines, Exelixis, Faron Pharmaceuticals, Fate Therapeutics, Ferring Pharmaceuticals, Five Prime Therapeutics, FLX Bio, Food and Drug Administration (FDA), Formosa Laboratories, Forty Seven, Fosun Kite Biotechnology, Fred Hutchinson Cancer Research Center, Fresenius Kabi Pharmaceuticals, Fuhong Hanlin, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Galapagos, Galaxy Biotech, Galderma, Gallus Biopharmaceuticals, GamaMabs Pharma, Genagon Therapeutics, Genentech, Generation Biotech, GeNeuro, Geneva Foundation, Genexine, Gen Ilac, Genmab, Genome and Company, Genor Biopharma, Genprex, GenScript USA, Georgetown University, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, Global Blood Therapeutics, Glycocept, Glycotope Biotechnology, Glythera, Goldfinch Bio, Goodwin Biotechnology, Gossamer Bio, Gradalis, Gritstone Oncology, GTP Technology, H-Immune, H3 Biomedicine, Hadasit Bioholdings, Halozyme Therapeutics, HanAll Pharmaceuticals, Harbour Antibodies, Harbour Biomed, Harvard Pilgrim Health Care, Heidelberg Pharma, Henlius Biotech, HiFiBio, Hikma Pharmaceuticals, Hoffmann La Roche, Hope Medicine, Horizon Discovery, Hospira, Humabs BioMed, Humanigen, Hummingbird Bioscience, Hutchison MediPharma, I-mab, i2 Pharmaceuticals, IBA Molecular Imaging, iBio, Icahn School of Medicine at Mount Sinai, Ichnos Sciences, Ichor Medical Systems, Iconic Therapeutics, IDBiologics, iDD Biotech, Idera Pharmaceuticals, Illumina, ImaginAb, ImCheck Therapeutics, ImClone Systems, Immatics Biotechnologies, ImmuneCyte Life Sciences, Immune Design, ImmuneOncia Therapeutics, Immune Pharmaceuticals, ImmuNext, ImmunoChina Pharmaceuticals, Immunocore, ImmunoGen, Immunomedics, Immunomic, Immunovaccine, Immutep, IMPACT Therapeutics, Incyte, InDevR, Infinity Pharmaceuticals, InflamaCORE, Innate Pharma, Innovate UK, Innovent Biologics, Inovio Pharmaceuticals, Inserm, Inserm Transfert, Institut Curie, Institute for Basic Science, Institute of Biophysics, Institut Pasteur, Intarcia Therapeutics, Integral Molecular, INTELLiSTEM, Intensity Therapeutics, International Consortium on Anti-Virals, Invenra, InxMed, IO Biotech, IONTAS, Ipca Laboratories, IRBM, ISA Pharmaceuticals, IsoTherapeutics, Israel Institute for Biological Research, iTeos Therapeutics, Izana Bioscience, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Janssen Sciences, Jasper Therapeutics, Jazz Pharmaceuticals, JHL Biotech, Jiangsu Alphamab, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jounce Therapeutics, Juno Therapeutics, Junshi Biosciences, Kadmon Pharmaceuticals, KAHR Medical, Kalbe Genexine Biologics, KBI BioPharma, Kelun-Biotech Biopharmaceutical, Kiniksa Pharmaceuticals, Kintor, Kite Pharma, Kodiak Sciences, Kolltan Pharmaceuticals, Kymab, Kyoto University, Kyowa Hakko Kirin, Laboratoires Thea, Laboratorios Liomont, LA Cell, LakePharma, Leads Biolabs, Leaf Biopharmaceutical, Leap Therapeutics, Lee's Pharmaceutical, Leica Biosystems, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, Libbs Farmaceutica, LifeArc, Ligand Pharmaceuticals, Liverpool School of Tropical Medicine, Livzon Mabpharm, Lonza, Lpath, Lumos Pharma, Lupagen, Lupin, Lupus Therapeutics, MAB Discovery, Mabion, MabQuest, MAbSilico, Mabspace Bioscience, MabVax Therapeutics, mAbXience, Macquarie University, Macrogenics, Magenta Therapeutics, Mapp Biopharmaceutical, Massachusetts General Hospital, Mayo Clinic, MD Anderson Cancer Center, Medgenics, Medicago, Medical Research Council, Medigen Biotechnology, Medimabs, MedImmune, Mediolanum, Mediomics, Medison Pharma, Medivation, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Merrimack Pharmaceuticals, Mersana Therapeutics, MicroConstants, MiniVax, Minomic, Mitra Biotech, Mitsubishi Tanabe Pharma, ModiQuest Research, Moleculin Biotech, Momenta Pharmaceuticals, MorphoSys, Morphotek, Mount Sinai Health System, MSD, Mundipharma, Mustang Bio, Mylan Laboratories, Mylan Pharmaceuticals, Myriad Genetics, myTomorrows, NantBioScience, NantCell, NantKwest, Nantong Jinghua Pharmaceutical, NantWorks, Nanyang Technological University, Nascent Biotech, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Heart, Lung and Blood Institute, National Institute for Bioprocessing Research and Training, National Institute for Viral Sidease Control and Prevention, National Institute of Allergy and Infectious Diseases, National Institute of Standards and Technology, National Institutes of Health, NCIC Clinical Trials Group, Nektar Therapeutics, NeoBiotechnologies, NeoImmuneTech, Neon Therapeutics, NETRIS Pharma, NeuClone, Neurimmune Therapeutics, Neuroblastoma and Medulloblastoma Translational Research, Newsummit Biopharma, Nexvet, Nkarta Therapeutics, Northern Biologics, Northwestern University, NovaRock Biotherapeutics, Novartis, Novasep, Novelogics Biotechnology, NovImmune, Novo Nordisk, Noxxon Pharma, Numab, Ohio Clinical Trials Collaborative, Ology Bioservices, Olympic Protein Technologies, Omeros, Oncobiologics, OncoCare Therapeutics, OncoImmune, Oncologie, Oncolytics Biotech, OncoMed Pharmaceuticals, OncoQuest, OncoSec Medical, Oncosynergy, Oncothyreon, Oncternal Therapeutics, Oncurious, Ono Pharmaceutical, Open Monoclonal Technology, Opthea, Organic Vaccines, OSE Immunotherapeutics, Otsuka, Oxford BioTherapeutics, PacificGMP, Pall Corporation, Pamlico Biopharma, Panacea Pharmaceuticals, Pandion Therapeutics, Panorama Research, Pascal Biosciences, Patheon, PATH Malaria Vaccine Initiative, PDS Biotechnology, Pelican Therapeutics, Peregrine Pharmaceuticals, Perelman School of Medicine, Perrigo, Personal Genome Diagnostics, Personalis, Pfenex, Pfizer, Phanes Therapeutics, PharmAbcine, Pharmacyclics, Pharmapark, PharmaPraxis, PhaseBio Pharmaceuticals, Pierre Fabre, PlantForm, Pneuma Respiratory, Polpharma, Portal Instruments, Poseida Therapeutics, Potenza Therapeutics, Precision Biologics, Prestige BioPharma, Probiodrug, ProBioGen, Progenics Pharmaceuticals, Prothena Biosciences, ProtoKinetix, Provention Bio, PULSALYS, Purolite, Q Therapeutics, Quantum Leap Health Care Collaborative, Queensland Institute of Medical Research (QIMR), Quest PharmaTech, R-Pharm, Regeneron Pharmaceuticals, Regenxbio, Rentschler Biotechnologie, Repligen, Rexahn Pharmaceuticals, Rezolute, Ridgeback Biotherapeutics, River Vision Development, Roche, Rockefeller University, Rocket Pharmaceuticals, Rockland Immunochemicals, Roivant Sciences, Roswell Park Cancer Institute, Royalty Pharma, RuiYi, SAB Therapeutics, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, San Diego Biomedical Research Institute, Sandoz, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, Sarah Cannon Research Institute, SATT Sud-Est, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Schrodinger, Sea Lane Biotechnologies, Seattle Genetics, Selecxine, Selexis, SELLAS Life Sciences Group, Sensei Biotherapeutics, Serum Institute of India, Seven and Eight Biopharmaceuticals, Sevion Therapeutics, SFJ Pharmaceuticals, Shandong Fontacea Pharmaceutical, ShanghaiTech University, Shenogen Pharma, Shenzhen Arimab Biopharmaceuticals, Shenzhen Chipscreen Biosciences, Shenzhen Hepalink Pharmaceutical, Shire Pharmaceuticals, Simcere Pharmaceuticals, Simon Fraser University, Sirnaomics, Small Business Innovation Research, Solentim, Sorrento Therapeutics, Sosei Heptares, Specialized Medical Services-oncology, Spring Bank Pharmaceuticals, STADA Arzneimittel, Stanford University, Strata Oncology, Strox Biopharmaceuticals, Sud Investments, Sun Pharmaceutical, Surface Oncology, Swedish Orphan, Swedish Orphan Biovitrum, Swixx Biopharma, Symphogen, Syndax Pharmaceuticals, Synlogic, Syros Pharmaceuticals, Taiho, TaiMed, Taiwan Ministry of Economic Affairs, Takeda Pharmaceutical, Talem Therapeutics, Tanabe Research Laboratories, TARIS Biomedical, Telix Pharmaceuticals, TeneoBio, Tesaro, Tessa Therapeutics, Tetragenetics, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, TFF Pharmaceuticals, TG Therapeutics, The International AIDS Vaccine Initiative, Theradiag, Theranyx, Theravectys, ThromboGenics, Tikcro Technologies, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, Tmunity Therapeutics, TONIX Pharmaceuticals, Torque Therapeutics, TOT BIOPHARM, TPG Capital, TRACON Pharmaceuticals, TransBio, Transcenta, Transgene, TransPerfect Life Sciences, Transporin, Trellis Bioscience, Tri-Institutional Therapeutics Discovery Institute, Trianni, Trieza Therapeutics, Trio Pharmaceuticals, Tsinghua University, Turgut Ilaclari, UCB, Ultragenyx Pharmaceuticals, UMass Memorial Medical Center, Unilife, Universite Claude Bernard Lyon, University College London, University of Bergen, University of British Columbia, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Cologne, University of Illinois at Chicago, University of Maryland Baltimore, University of Massachusetts Medical School, University of Minnesota, University of New Mexico, University of Nottingham, University of Pennsylvania, University of Rochester, University of Texas, University of Wisconsin Carbone Cancer Center (UWCCC), Unum Therapeutics, Uppsala University, UroGen Pharma, US Army Medical Research Institute of Infectious Diseases, US Government, Utrecht University, Vaccinex, Valeant Pharmaceuticals, Valneva, Vanderbilt University, Vaximm, Vcell Healthcare, Vect-Horus, Vedanta Biosciences, Velabs Therapeutics, Ventana Medical Systems, Verastem, Verseau Therapeutics, VIB, Vical, Viela Bio, Vinnova, Viralytics, Virbac, Vir Biotechnology, Visterra, Vitaeris, Voyager Therapeutics, Vyera Pharmaceuticals, Vyriad, Wilex, WindMIL Therapeutics, Wistar Institute, World Health Organization, WuXi Biologics, XBiotech, Xbrane Bioscience, xCella Biosciences, Xencor, Xoma, Yale University, Yas Holding, Yeda Research and Development Company, Yissum Research Development, YL Biologics, Yoshindo, ZAI Laboratory, Zenoaq, Zenyaku Kogyo, Zhejiang Bossan Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zoetis, Zydus Cadila, Zymeworks, ZyVersa Therapeutics


More Publications